AN UPDATE ON ABBOTT'S WORK ON COVID-19 TESTING

An Update on Abbott's Work on COVID-19 Testing

Aug 14 2020

Abbott is continuing to ramp up production of our COVID-19 tests across our five platforms and ship to more customers in the U.S., helping healthcare providers on the front lines battle this pandemic.

Here's an update:

ID NOW – Our rapid, portable testing instrument used in urgent care clinics, hospital emergency departments, and physicians' offices

  • We have shipped 7 million of our rapid ID NOW tests to all 50 states, Washington DC, Puerto Rico and the Pacific Islands. The majority of these tests have been sent to outbreak hotspots and we've asked that customers prioritize frontline health care workers and first responders.

Molecular lab tests – Our high-volume molecular laboratory instruments to detect novel coronavirus

  • We have shipped more than 6 million molecular lab tests (m2000 and Alinity m) in the U.S.

Antibody lab tests – Our lab-based antibody blood tests to help determine if a person was previously infected with the virus that causes COVID-19

  • We have shipped more than 13 million ARCHITECT and AlinityTM i COVID-19 antibody tests to customers across the U.S. We are also shipping our antibody tests to several other countries.

AUG 5 2020

Abbott is continuing to ramp up production of our COVID-19 tests across our five platforms and ship to more customers in the U.S., helping healthcare providers on the front lines battle this pandemic.

Here's an update:

ID NOW – Our rapid, portable testing instrument used in urgent care clinics, hospital emergency departments, and physicians' offices

  • We have shipped 6.5 million of our rapid ID NOW tests to all 50 states, Washington DC, Puerto Rico and the Pacific Islands. The majority of these tests have been sent to outbreak hotspots and we've asked that customers prioritize frontline health care workers and first responders.

Molecular lab tests – Our high-volume molecular laboratory instruments to detect novel coronavirus

  • We have shipped more than 5.6 million molecular lab tests (m2000 and Alinity m) in the U.S.

Antibody lab tests – Our lab-based antibody blood tests to help determine if a person was previously infected with the virus that causes COVID-19

  • We have shipped more than 13 million ARCHITECT and AlinityTM i COVID-19 antibody tests to customers across the U.S. We are also shipping our antibody tests to several other countries.

JUL 17 2020

Abbott is continuing to ramp up production of our COVID-19 tests across our five platforms and ship to more customers, helping healthcare providers on the front lines battle this pandemic.

Here's an update:

ID NOW – Our rapid, portable testing instrument used in urgent care clinics, hospital emergency departments, and physicians' offices

  • We have shipped 5.3 million of our rapid ID NOW tests to all 50 states, Washington DC, Puerto Rico and the Pacific Islands. The majority of these tests have been sent to outbreak hotspots and we've asked that customers prioritize frontline health care workers and first responders.

Molecular lab tests – Our high-volume molecular laboratory instruments to detect novel coronavirus

  • We have shipped 4.5 million molecular lab tests (m2000 and Alinity m) in the U.S.

Antibody lab tests – Our lab-based antibody blood tests to help determine if a person was previously infected with the virus that causes COVID-19

  • We have shipped 12.6 million ARCHITECT and AlinityTM i COVID-19 antibody tests to customers across the U.S. We are also shipping our antibody tests to several other countries.

JUL 1 2020

Abbott is continuing to ramp up production of our COVID-19 tests across our five platforms and ship to more customers, helping healthcare providers on the front lines battle this pandemic.

Here's an update:

ID NOW – Our rapid, portable testing instrument used in urgent care clinics, hospital emergency departments, and physicians' offices

  • We have shipped nearly 4.5 million of our rapid ID NOW tests to all 50 states, Washington DC, Puerto Rico and the Pacific Islands. The majority of these tests have been sent to outbreak hotspots and we've asked that customers prioritize frontline health care workers and first responders.

Molecular lab tests – Our high-volume molecular laboratory instruments to detect novel coronavirus

  • We have shipped nearly 4 million molecular lab tests (m2000 and Alinity m) in the U.S.

Antibody lab tests – Our lab-based antibody blood tests to help determine if a person was previously infected with the virus that causes COVID-19

  • We have shipped nearly 12.1 million ARCHITECT and Alinity™ i COVID-19 antibody tests to customers across the U.S. We received CE Mark for the ARCHITECT test and are shipping to several other countries.

JUN 19 2020

Abbott is continuing to ramp up production of our COVID-19 tests across our five platforms and ship to more customers, helping healthcare providers on the front lines battle this pandemic.

Here's an update:

ID NOW – Our rapid, portable testing instrument used in urgent care clinics, hospital emergency departments, and physicians' offices

  • We have shipped more than 3.7 million of our rapid ID NOW tests to all 50 states, Washington DC, Puerto Rico and the Pacific Islands. The majority of these tests have been sent to outbreak hotspots and we've asked that customers prioritize frontline health care workers and first responders.

Molecular lab tests – Our high-volume molecular laboratory instruments to detect novel coronavirus

  • We have shipped more than 3.4 million molecular lab tests (m2000 and Alinity m) in the U.S.

Antibody lab tests – Our lab-based antibody blood tests to help determine if a person was previously infected with the virus that causes COVID-19

  • We have shipped 11.8 million ARCHITECT and Alinity™ i COVID-19 antibody tests to customers across the U.S. We received CE Mark for the ARCHITECT test and are shipping to several other countries.

JUN 9 2020

Abbott is continuing to ramp up production of our COVID-19 tests across our five platforms and ship to more customers, helping healthcare providers on the front lines battle this pandemic.

Here's an update:

ID NOW – Our rapid, portable testing instrument used in urgent care clinics, hospital emergency departments, and physicians' offices

  • We have shipped 3.3 million of our rapid ID NOW tests to all 50 states, Washington DC, Puerto Rico and the Pacific Islands. The majority of these tests have been sent to outbreak hotspots and we've asked that customers prioritize frontline health care workers and first responders.

Molecular lab tests – Our high-volume molecular laboratory instruments to detect novel coronavirus

  • We have shipped nearly 3.1 million molecular lab tests (m2000 and Alinity m) in the U.S.

Antibody lab tests – Our lab-based antibody blood tests to help determine if a person was previously infected with the virus that causes COVID-19

  • We have shipped 11.6 million ARCHITECT and Alinity™ i COVID-19 antibody tests to customers across the U.S. We received CE Mark for the ARCHITECT test and are shipping to several other countries.

MAY 28 2020

Abbott is continuing to ramp up production of our COVID-19 tests across our five platforms and ship to more customers, helping healthcare providers on the front lines battle this pandemic.

Here's an update:

ID NOW – Our rapid, portable testing instrument used in urgent care clinics, hospital emergency departments, and physicians' offices

  • We have shipped nearly 2.5 million of our rapid ID NOW tests to all 50 states, Washington DC, Puerto Rico and the Pacific Islands. The majority of these tests have been sent to outbreak hotspots and we've asked that customers prioritize frontline health care workers and first responders.
  • We're currently manufacturing 50,000 tests per day, plan to increase ID NOW manufacturing capacity to 2 million tests a month by June and are working to expand beyond that.

Molecular lab tests – Our high-volume molecular laboratory instruments to detect novel coronavirus

  • We recently received U.S. FDA Emergency Use Authorization for Alinity m and have shipped 2.8 million molecular lab tests (m2000 and Alinity m) in the U.S.

Antibody lab tests – Our lab-based antibody blood tests to help determine if a person was previously infected with the virus that causes COVID-19

  • We have shipped nearly 11.4 million ARCHITECT and AlinityTM i  COVID-19 antibody tests to customers across the U.S. We also recently announced CE Mark for the ARCHITECT test and are shipping to several other countries.

MAY 11 2020

Today, Abbott gained EUA for our Alinity i COVID-19 antibody test and we continue to ramp up production of our COVID-19 tests across our four platforms and ship to more customers, helping healthcare providers on the front lines battle this pandemic.

Here's an update:

ID NOW – Our rapid, portable testing instrument used in urgent care clinics, hospital emergency departments, and physicians' offices

  • We have shipped more than 1.7 million of our rapid ID NOW tests to all 50 states, Washington DC, Puerto Rico and the Pacific Islands. The majority of these tests have been sent to outbreak hotspots and we've asked that customers prioritize frontline health care workers and first responders.
  • We're currently manufacturing 50,000 tests per day, plan to increase ID NOW manufacturing capacity to 2 million tests a month by June and are working to expand beyond that.

m2000 – Our large, high-volume laboratory instrument

  • We have shipped more than 2 million tests to customers across the U.S. We're also shipping these tests to customers throughout the world.
  • There are approximately 200 m2000 instruments in hospital, academic center and reference labs throughout the U.S.

Antibody tests – Our lab-based antibody blood tests to help determine if a person was previously infected with the virus that causes COVID-19.

  • We have shipped more than 7.2 million ARCHITECT tests to customers across the U.S. We also recently announced CE Mark for the ARCHITECT test and are shipping to several other countries.
  • Our AlinityTM i COVID-19 antibody test just received U.S. FDA Emergency Use Authorization, and we've started shipping the tests to our customers.

MAY 4 2020

Abbott continues to expand accessibility to our COVID-19 tests by ramping up production and shipping to more customers, helping healthcare providers on the front lines.

Here's an update:

ID NOW – Our rapid, portable testing instrument used in urgent care clinics, hospital emergency departments, and physicians' offices

  • We have shipped nearly 1.4 million of our rapid ID NOW tests to all 50 states, Washington DC, Puerto Rico and the Pacific Islands. The majority of these tests have been sent to outbreak hotspots and we've asked that customers prioritize frontline health care workers and first responders.
  • We're currently manufacturing 50,000 tests per day, plan to increase ID NOW manufacturing capacity to 2 million tests a month by June and are working to expand beyond that.

m2000 – Our large, high-volume laboratory instrument

  • We have shipped 1.9 million tests to customers across the U.S. We're also shipping these tests to customers throughout the world.
  • There are approximately 200 m2000 instruments in hospital, academic center and reference labs throughout the U.S.

Antibody test – Our lab-based antibody blood test that helps determine if a person was previously infected with the virus that causes COVID-19.

  • We have shipped 4.6 million tests to customers across the U.S. Last week, Abbott announced CE Mark for the antibody test and began shipping tests to several European countries.
  • Abbott plans to ramp up to 20 million antibody tests in June and beyond, and expand our testing capabilities to our Alinity i lab system.

APR 24 2020

Abbott continues to expand accessibility to our COVID-19 tests by ramping up production and shipping to more customers, helping healthcare providers on the front lines.

Here's an update:

ID NOW – Our rapid, portable testing instrument used in urgent care clinics, hospital emergency departments, and physicians' offices

  • We have shipped more than 1 million of our rapid ID NOW tests to all 50 states, Washington DC, Puerto Rico and the Pacific Islands. The majority of these tests have been sent to outbreak hotspots and we've asked that customers prioritize frontline health care workers and first responders.
  • We're currently manufacturing 50,000 tests per day, plan to increase ID NOW manufacturing capacity to 2 million tests a month by June and are working to expand beyond that.

m2000 – Our large, high-volume laboratory instrument

  • We have shipped more than 1.4 million tests to customers across the U.S. We're also shipping these tests to customers throughout the world.
  • There are approximately 200 m2000 instruments in hospital, academic center and reference labs throughout the U.S.

Antibody test – Last week, Abbott announced and began shipping a lab-based antibody blood test that helps determine if a person was previously infected with the virus that causes COVID-19.

  • We have shipped nearly 2.5 million tests to customers across the U.S.
  • Abbott plans to ramp up to 20 million antibody tests in June and beyond, and expand our testing capabilities to our Alinity i lab system.

APR 15 2020

Abbott launched its third COVID-19 test and will start shipping in the U.S.

Here are the details:

This new test is a serology test – also called an antibody test – and helps to detect the IgG antibody to SARS-CoV-2. Detecting these IgG antibodies will help determine if a person was previously infected with the virus that causes COVID-19.

  • We're significantly scaling up our manufacturing for antibody testing and expect to ship close to 1 million tests to U.S. customers this week and 4 million of the antibody tests during April.
  • Abbott plans to ramp up to 20 million antibody tests in June and beyond, and expand our testing capabilities to our Alinity i lab system.

APR 13 2020

Abbott has continued to expand accessibility to our COVID-19 tests by ramping up production and shipping to more customers, helping healthcare providers on the front lines.

Here’s an update:

ID NOW – Our rapid, portable testing instrument used in urgent care clinics, hospital emergency departments, and physicians' offices

  • Through Saturday, April 11, we have shipped 566,000 of our rapid ID NOW tests to all 50 states, Washington DC, Puerto Rico and the Pacific Islands. The majority of these tests have been sent to outbreak hotspots and we've asked that customers prioritize frontline health care workers and first responders.
  • We're currently manufacturing 50,000 tests per day, plan to increase ID NOW manufacturing capacity to 2 million tests a month by June and are working to expand beyond that.

m2000 – Our large, high-volume laboratory instrument

  • We have shipped more than 1 million tests to customers across the U.S. We're also shipping these tests to customers throughout the world.
  • There are approximately 200 m2000 instruments in hospital, academic center and reference labs throughout the U.S.

APR 3 2020

We began distributing our rapid point-of-care COVID-19 tests for our ID NOW system on Tuesday, March 31. By the end of today we will have shipped more than 190,000 rapid tests to customers in 21 states. We're producing 50,000 tests every day now and we'll continue to ship daily to more customers in more places.

We're also continuing to ramp up our ID NOW manufacturing and plan to increase capacity to 2 million tests a month by June and are working to expand beyond that.

We've been in close coordination with U.S. federal and state authorities – as well as our customers in urgent care clinics, hospital emergency departments, and physicians' offices – to ensure ID NOW instruments and tests are sent to outbreak hotspots. While customers ultimately determine how our tests are deployed, we would like to prioritize frontline healthcare workers and first responders because we believe this is the best way to support the nation’s healthcare infrastructure.

Beyond delivering our tests, we are also doing all we can to monitor the deployment of the rapid tests and to avoid hoarding or price-gouging in secondary markets.

A rapid test is one part of the solution, not the only one. Our m2000 RealTime molecular laboratory instrument, for example, can run 470 tests a day and give results in about 6.5 hours. Importantly, we're now able to produce 1 million tests a week for our m2000 laboratory system. To date, we've shipped nearly 1 million tests to customers across the U.S. and have begun to ship tests to other countries around the world.

At Abbott, we have a saying, "we make our products as if they are for our own families." We and our families live in the same communities around the country and around the world that you do. We understand our responsibility. We know the stakes. We know 50,000 rapid tests a day are not enough. We can see the gaps also.

But we're not stopping here. We’re working 24/7 to make as many tests as we can and create the next round of needed tests. Our scientists continue to work on additional COVID-19 tests across the spectrum of our diagnostic instruments, including lateral flow and antibody tests. Our goal is to provide more testing, and to get our tests to more places around the world.

We're proud to be able to contribute in this fight and are committed for the duration.

 

true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?